Azoospermia occurs in almost all male Hodgkin’s lymphoma (HL) patients after chemotherapy with alkylating agent-containing regimens (e.g., MOPP regimen, BEACOPP regimen), with only a very small number of patients recovering sperm viability. Short-term azoospermia occurs in 1/3 of patients treated with ABVD regimens, with full recovery occurring in all cases. Sperm cryopreservation is possible prior to treatment for men who will be treated with alkylating agents and who wish to have children, but German Hodgkin’s lymphoma researchers found that 77% of poorly differentiated HL patients already had sperm abnormalities prior to treatment. The Dutch study found that female HL patients treated with MOPP or a modified regimen had a cumulative risk of menopause by age 40 of 48%. At a median follow-up of 3.2 years, 51.4% of patients treated with 8 cycles of high-dose BEACOPP regimen chemotherapy developed amenorrhea. In contrast, fertility was better protected in female patients treated with the ABVD regimen. patients more than 3 years after the end of ABVD treatment did not show any difference in pregnancy rates compared to healthy controls. Patients treated with an alkylating agent-containing regimen can become pregnant through in vitro fertilization with cryopreserved embryos. The current first-line treatment option for Hodgkin’s lymphoma in clinical practice is ABVD.